A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia

Neurology

Volumn 53, Issue 5, 1999, Pages 946-955

  De Deyn, P P ^g   Rabheru, K ^a   Rasmussen, A ^b   Bocksberger, J P ^c   Dautzenberg, P L J ^d   Eriksson, S ^e   Lawlor, B A ^f  

^a London Psychiatric Hospital   (Canada)

^b FREDERIKSBERG HOSPITAL   (Denmark)

^c GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^d JEROEN BOSCH HOSPITAL   (Netherlands)

^e UMEÅ UNIVERSITY   (Sweden)

^f ST JAMES S HOSPITAL   (Ireland)

^g UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Aggression; Behavioral symptoms; Dementia; Extrapyramidal symptoms; Risperidone

Indexed keywords

RISPERIDONE;

ADULT; AGED; AGGRESSION; ARTICLE; BEHAVIOR DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0033595555     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.5.946     Document Type: Article

References (39)

1. Reisberg B, Borenstein J, Franssen E, et al. Remediable behavioral symptomatology in Alzheimer's disease. Hosp Commun Psychiatry 1986;37:1199-1201.
2. Reisberg B, Borenstein J, Salob SP, et al. Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. J Clin Psychiatry 1987;48(suppl 5):9-15.
3. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th ed. Washington, DC: American Psychiatric Association, 1994.
4. Jost BC, Grossberg GT. The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J Am Geriatr Soc 1996;44:1078-1081.
5. Tariot PN, Blazina L. The psychopathology of dementia. In: Morris JC, ed. Handbook of dementing illnesses. New York: Marcel Dekker, 1994;461-475.
6. Tariot PN, Mack JL, Patterson MB, et al. The behavior rating scale for dementia of the consortium to establish a registry for Alzheimer's disease. Am J Psychiatry 1995;152:1349-1357.
7. Reisberg B. Memory dysfunction and dementia: diagnostic considerations. In: Salzman C, ed. Clinical geriatric psychopharmacology. 2nd ed. Baltimore: Williams & Wilkins, 1992; 255-276.
8. Eastley R, Wilcock GK. Prevalence and correlates of aggressive behaviours occurring in patients with Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:484-487.
9. Coen RF, Swanwick GRJ, O'Boyle CA, Coakley D. Behaviour disturbance and other predictors of carer burden in Alzheimer's disease. Int J Geriatr Psychiatry 1997;12:331-336.
10. Donaldson C, Tarrier N, Burns A. The impact of the symptoms of dementia on caregivers. Br J Psychiatry 1997;170:62-68.
11. US Department of Health and Human Services. Alzheimer's Disease: Report of the Secretary's Task Force on Alzheimer's Disease. September 1984:23-33.
12. Ferris SH, Steinberg G, Shulman E, et al. Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counseling. Home Health Care Serv Quarterly 1987;8:23-51.
13. US Bureau of the Census. International database: Table 094. Midyear population, by age and sex. Washington, DC; January 1999.
14. Ritchie K, Kildea D, Robine J-M. The relationship between age and the prevalence of senile dementia: a meta-analysis of recent data. Int J Epidemiol 1992;21:763-769.
15. American Psychiatric Association. Work Group on Alzheimer's Disease and Related Dementias. Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. Am J Psychiatry 1997;154(suppl 5):1-39.
16. Kunik ME, Puryear L, Orengo CA, et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998; 13:29-34.
17. Schneider LS, Pollock VE, Lyness SA. A meta-analysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 1990;38:553-563.
18. Goldberg RJ, Goldberg J. Antipsychotics for dementia-related behavioral disturbances in elderly institutionalized patients. Clin Geriatr 1996;4:58-68.
19. Oberholzer AF, Hendriksen C, Monsch AU, et al. Safety and effectiveness of low-dose clozapine in psychogeriatric patients: a preliminary study. Int Psychogeriatr 1992;4:187-195.
20. Goldberg RJ, Goldberg J. Risperidone for dementia-related disturbed behavior in nursing home residents: a clinical experience. Int Psychogeriatr 1997;9:65-68.
21. Kopala LC, Honer WG. The use of risperidone in severely demented patients with persistent vocalizations. Int J Geriatr Psychiatry 1997;12:73-77.
22. Jeanblanc W, Davis YB. Risperidone for treating dementia-associated aggression. Am J Psychiatry 1995;152:1239. Letter.
23. Madhusoodanan S, Brenner R, Araujo L, Abaza A. Efficacy of risperidone treatment for psychoses associated with schizophrenia, schizoaffective disorder, bipolar disorder, or senile dementia in 11 geriatric patients: a case series. J Clin Psychiatry 1995;56:514-518.
24. Satterlee WG, Reams SG, Burns PR, et al. A clinical update on olanzapine treatment in schizophrenia and in elderly Alzheimer's disease patients. Psychopharmacol Bull 1995;31:534. Abstract.
25. Reisberg B. Functional assessment staging (FAST). Psychopharmacol Bull 1988;24:653-659.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
27. Reisberg B, Franssen E, Sclan SG, et al. Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci 1989;54:95-112.
28. Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare, 1976. Publication ADM 76-338.
29. Cohen-Mansfield J, Marx MS, Rosenthal AS. A description of agitation in a nursing home. J Gerontol 1989;44:M77-M84.
30. Chouinard G, Ross-Chouinard A, Annable L, Jones BD. The Extrapyramidal Symptom Rating Scale. Can J Neurol Sci 1980;7:233.
31. Finkel SI, ed. Behavior and psychological signs and symptoms of dementia: implications for research and treatment. Int Psychogeriatr 1996;8(suppl 3):215-242.
32. Max W. The cost of Alzheimer's disease. Will drug treatment ease the burden? PharmacoEconomics 1996;9:5-10.
33. Leysen JE, Gommeren W, Eens A, et al. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 1988; 247:661-670.
34. Mintzer JE, Hoernig KS, Mirski DF. Treatment of agitation in patients with dementia. Clin Geriatr Med 1998;14:147-175.
35. Chouinard G, Jones B, Remington G, et al. A Canadian multi-center placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol 1993;13:25-40.
36. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-835.
37. Peuskens J, the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-726.
38. Risperdal. Physicians' desk reference. Montvale, NJ: Medical Economics Data Production Company, 1998.
39. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry 1995;52:756-765.